IFJPY vs BBIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IFJPY · INFORMA PLC SPON ADR EACH REPR 2 ORD GBP4.35$22.30 ▼ 2.02%
BBIO · BridgeBio Pharma$74.29 ▲ 0.03%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IFJPY -12.2%
- BBIO +18.3%
Head to head
| Metric | IFJPY | BBIO |
|---|---|---|
| Price | $22.30 | $74.29 |
| Change today | ▼ 2.02% | ▲ 0.03% |
| Market cap | $14.47B | $14.47B |
| Return, 3 months | -8.9% | -12.3% |
| Return, year to date | -5.0% | -2.9% |
| Return, 1 year | -13.2% | +20.2% |
| P/E (TTM) | 48.5 | – |
| P/B | 1.8 | -5.6 |
| P/E percentile vs own 5y | – | 0th |
| Dividend yield | 2.69% | – |
| Revenue growth (YoY, latest qtr) | – | +120.4% |
| Net profit growth (YoY) | – | +15.2% |
| Gross margin | – | 94.4% |
| Operating margin | – | -67.0% |
| Net margin | – | -97.0% |
| Return on equity | – | – |
| Analyst target vs. price | – | +47.7% |
| Analyst buy share | – | 94% |
| RSI (14) | 44 | 60 |
| 30-day volatility | 33.3% | 35.2% |
| Max drawdown, 1 year | -26.7% | -29.8% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BBIO is the largest of the group by market value.
- BBIO has returned the most over the past year.
- IFJPY has been the calmest stock over the last 30 days.